Doctor-led aesthetics in Sutton Coldfield
MDr MaryamAesthetics

Polynucleotides

Polynucleotides for melasma: what did the split-face trial actually show?

A small randomised trial tested topical polynucleotides after radiofrequency microneedling for melasma, but found no significant added benefit over the device treatment alone.

5 minute read

Melasma needs a diagnosis, not a product label

Melasma causes flat, irregular areas of increased facial pigmentation, often on the cheeks, forehead, upper lip or chin. Light exposure, hormones, pregnancy, some medicines and individual predisposition may contribute. Other pigment changes can look similar, so a changing, raised, bleeding or otherwise unusual lesion should be medically assessed rather than treated as melasma.

Melasma is usually persistent and can recur after improvement. The British Association of Dermatologists identifies daily light protection as central to management because affected skin darkens with exposure. A cosmetic procedure cannot replace an appropriate diagnosis, broad-spectrum sunscreen, visible-light protection where relevant or discussion of established medical options with a suitably qualified clinician.

How was PN used in the trial?

A double-blind, randomised split-face pilot study enrolled 30 adults with melasma and Fitzpatrick skin types III to V. All participants were women. Both sides of the face received three sessions of invasive radiofrequency microneedling at two-week intervals; PN was applied to one randomly assigned side afterwards, while saline was applied to the other.

This distinction matters. The study did not test PN injections on their own, nor did it compare injected PN with established melasma treatment. The device created microscopic channels before the PN was applied. Findings from that combined protocol cannot be transferred automatically to a different product, concentration, injection depth or treatment schedule.

Both sides improved, but PN did not add a significant benefit

Researchers measured pigment, redness, roughness and melasma severity and followed participants for up to six months. Twenty-six completed the final assessment. Both the PN and saline sides improved from baseline, but there was no statistically significant difference between sides. The authors concluded that adding PN was not superior to radiofrequency microneedling alone for melasma.

Three participants experienced recurrence at two, three or four months after the final session. This illustrates the relapsing nature of melasma, but it should not be converted into a general recurrence percentage: the study was small and four participants did not complete six-month follow-up. It also cannot show whether improvement came from the device, aftercare, light protection or several influences together.

Why this evidence has important limits

A split-face design helps each participant act as her own control, reducing differences between people. However, pigment can vary across the two sides of one face, and both sides received the active device procedure. The sample included only Thai women with skin types III to V, so results may not apply to men, other skin types or different clinical settings.

One pilot trial cannot establish that PN treats melasma, select an ideal protocol or exclude uncommon adverse effects. It is also incorrect to treat smoother texture as proof that pigmentation has improved because these are different outcomes. The most defensible reading is that this particular PN application did not demonstrate added benefit over the paired control treatment.

Downtime and the possibility of pigment worsening

Radiofrequency microneedling can cause temporary discomfort, redness, swelling, dryness, pinpoint bleeding or crusting. Infection, scarring and post-inflammatory pigment change are less common but important possibilities. In melasma-prone skin, inflammation itself may worsen uneven pigmentation, so device choice, settings, skin type, preparation and aftercare require individual consideration.

Because PN was applied after the device rather than injected, this trial does not define injection-specific downtime. Separate PN injections can cause stinging, tenderness, raised points, swelling and bruising, with infection and other complications possible. Increasing pain, spreading heat or redness, discharge, fever, blistering, marked colour change, eye pain or any visual symptom needs prompt clinical assessment.

Consultation should set realistic priorities

Assessment should confirm the pigment pattern and review onset, pregnancy or hormonal factors, medicines, previous treatments, light exposure, skin sensitivity, tendency to develop post-inflammatory pigmentation and realistic goals. Active infection or inflammation, impaired healing, pregnancy or breastfeeding and relevant medical history may alter suitability or mean that a procedure should be postponed or avoided.

A responsible consultation explains established options, alternatives, expected maintenance, total treatment burden, downtime and the possibility of recurrence or worsening. It may recommend dermatology review, a different approach or no procedure. GMC guidance requires cosmetic interventions to be based on current evidence and marketed without unjustifiable claims; this trial does not support promising PN injections as a proven melasma treatment.

← Back to the journal

Personalised medical assessment

Questions about treatment?

Book a consultation to discuss your concerns, health and treatment options without pressure.

Free consultation – a £1 booking fee secures your appointment